Nurix is a Brisbane, California biopharmaceutical company developing cancer and inflammation drugs that remove disease-causing proteins. NRIX reports earnings on Wed, Jan 27, 2027. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 16 | HC Wainwright & Co. | Target raised | Buy | |
| Oct 13 | RBC Capital | Target lowered | Buy | |
| Oct 13 | Oppenheimer | Maintained | Buy | |
| Oct 13 | Truist Securities | Target lowered | Buy | |
| Oct 13 | Baird | Target raised | Buy |
Whale Options Flow
90DNo whale options trades in NRIX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRIX is in one of them and how their past NRIX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NRIX in an article yet. Here's the latest on the wider market.
About Nurix Therapeutics
Nurix is a clinical stage biopharmaceutical company based in Brisbane, California. It develops medicines based on targeted protein degradation, a approach that removes disease-causing proteins, with a focus on cancer and inflammatory conditions. Its lead candidate, bexobrutideg, is being studied in patients with relapsed or refractory chronic lymphocytic leukemia. The company also works with large drug makers, including Gilead, Sanofi and Pfizer, on collaborations that use its platform, which combines DNA encoded libraries with artificial intelligence, to find new drug candidates.
- Headquarters
- Brisbane, CA
- Founded
- 2012
- Website
- nurixtx.com ↗